1697 related articles for article (PubMed ID: 24731669)
1. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
Yki-Järvinen H
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
[TBL] [Abstract][Full Text] [Related]
3. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
[TBL] [Abstract][Full Text] [Related]
4. A population-based study on the prevalence of NASH using scores validated against liver histology.
Hyysalo J; Männistö VT; Zhou Y; Arola J; Kärjä V; Leivonen M; Juuti A; Jaser N; Lallukka S; Käkelä P; Venesmaa S; Simonen M; Saltevo J; Moilanen L; Korpi-Hyövalti E; Keinänen-Kiukaanniemi S; Oksa H; Orho-Melander M; Valenti L; Fargion S; Pihlajamäki J; Peltonen M; Yki-Järvinen H
J Hepatol; 2014 Apr; 60(4):839-46. PubMed ID: 24333862
[TBL] [Abstract][Full Text] [Related]
5. A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.
Targher G; Byrne CD
Metab Syndr Relat Disord; 2015 Aug; 13(6):235-8. PubMed ID: 25714786
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and risk of type 2 diabetes.
Lallukka S; Yki-Järvinen H
Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):385-95. PubMed ID: 27432073
[TBL] [Abstract][Full Text] [Related]
7. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome.
Wainwright P; Byrne CD
Int J Mol Sci; 2016 Mar; 17(3):367. PubMed ID: 26978356
[TBL] [Abstract][Full Text] [Related]
9. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
Yki-Järvinen H
Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
12. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.
Kotronen A; Peltonen M; Hakkarainen A; Sevastianova K; Bergholm R; Johansson LM; Lundbom N; Rissanen A; Ridderstråle M; Groop L; Orho-Melander M; Yki-Järvinen H
Gastroenterology; 2009 Sep; 137(3):865-72. PubMed ID: 19524579
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
14. Role of diet and nutritional management in non-alcoholic fatty liver disease.
Fan JG; Cao HX
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes.
Käräjämäki AJ; Bloigu R; Kauma H; Kesäniemi YA; Koivurova OP; Perkiömäki J; Huikuri H; Ukkola O
Metabolism; 2017 Jan; 66():55-63. PubMed ID: 27423871
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?
Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH
Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761
[TBL] [Abstract][Full Text] [Related]
17. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
Yki-Järvinen H
Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease: defining a common problem.
Gasbarrini G; Vero V; Miele L; Forgione A; Hernandez AP; Greco AV; Gasbarrini A; Grieco A
Eur Rev Med Pharmacol Sci; 2005; 9(5):253-9. PubMed ID: 16231586
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Stefan N; Häring HU; Cusi K
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
[TBL] [Abstract][Full Text] [Related]
20. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
